The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: a preliminary study.

Gynecologic Oncology Unit, Catholic University of Sacred Heart, Rome, Italy, and Department of Obstetrics and Gynecology, University Hospital Katholieke Universiteit Leuven, Belgium.
Ultrasound in Obstetrics and Gynecology (Impact Factor: 3.56). 05/2007; 29(5):512-6. DOI: 10.1002/uog.4013
Source: PubMed

ABSTRACT To describe sonographically the distribution patterns of a second-generation contrast agent in the microcirculation of unilocular and multilocular ovarian masses with papillary projections, and to investigate whether qualitative evaluation of the passage of the contrast agent can improve the performance of sonography in distinguishing between benign and malignant masses with papillary projections.
Thirty-three patients with unilocular or multilocular ovarian masses with papillary projections were enrolled into the study in three clinical centers. The contrast-enhanced transvaginal examination was performed using 'Contrast Tuned Imaging' (CnTI) technology and SonoVue ultrasound contrast agent.
Twenty-four (73%) lesions were benign, eight (24%) were borderline ovarian tumors, and one patient presented with an endometrioid ovarian adenocarcinoma. On color and power Doppler examinations the presence of vessels was demonstrated in 17 papillary projections, while on CnTI-SonoVue examination, the presence of vessels was shown in these 17 and in six additional cases. In all cases with absent papillary perfusion after SonoVue intravenous injection, the cyst wall appeared unequivocally regular. The sensitivity and specificity of conventional color Doppler examination with regard to malignancy were 100% and 67% and the positive and negative likelihood ratios were 3.03 and 0.16, respectively. For the contrast-enhanced examination the corresponding values were 100%, 42%, 1.7 and 0.26. The difference in specificity was statistically significant (P<0.05) because 14 cases, in which papillary perfusion was detected after SonoVue injection, proved to be benign on pathological examination.
Qualitative evaluation of blood circulation in papillary projections using CnTI-SonoVue examination does not improve the discrimination of benign from borderline/malignant ovarian masses with papillary projections.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is the most lethal of the gynecologic malignancies. Because ovarian cancer symptoms are subtle and nonspecific, the diagnosis is often delayed until the disease is well advanced. Overall 5-year survival is a rather dismal 50% but can be improved to greater than 90% if the disease is confined to the ovary at the time of diagnosis (generally in fewer than 25% of patients). Effective screening tools are currently not available. Owing to the rather low incidence of the disease in the general population, potential screening tests must provide very high specificity to avoid unnecessary interventions in false-positive cases. This article reviews currently available serum biomarkers and imaging tests for the early detection of ovarian cancer and provides an outlook on the potential improvements in these noninvasive diagnostic tools that may lead to successful implementation in a screening program. Supplemental material:
    Radiology 05/2011; 259(2):329-45. · 6.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Borderline ovarian tumors represent a heterogeneous group of noninvasive tumors of uncertain malignant potential with characteristic histology. They occur in younger women, are present at an early stage, and have a favorable prognosis, but symptomatic recurrence and death may be found as long as 20 years after therapy in some patients. The molecular changes in borderline ovarian tumors indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas). The pathological stage of disease and subclassification of extraovarian disease into invasive and noninvasive implants, together with the presence of postoperative macroscopic residual disease, appear to be the major predictor of recurrence and survival. However, it should be emphasized that the most important negative prognostic factor for recurrence is just the use of conservative surgery, but without any impact on patient survival because most recurrent diseases are of the borderline type-easily curable and with an excellent prognosis. Borderline tumors are difficult masses to correctly preoperatively diagnose using imaging methods because their macroscopic features may overlap with invasive and benign ovarian tumors. Over the past several decades, surgical therapy has shifted from a radical approach to more conservative treatment; however, oncologic safety must always be balanced. Follow-up is essential using routine ultrasound imaging, with special attention paid to the remaining ovary in conservatively treated patients. Current literature on this topic leads to a number of controversies that will be discussed thoroughly in this article, with the aim to provide recommendations for the clinical management of these patients.
    The Oncologist 09/2012; · 4.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this article is to review the current indications for the use of contrast agents in ultrasonography in imaging departments with reference to the guidelines and recommendations recently published by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). The article begins with a brief description of currently available contrast agents, of their adverse effects and contraindications, and of the specific techniques that enable the signal emitted from the microbubbles in the contrast to be detected. Next, we review the indications for ultrasound contrast agents both in the liver (detecting and characterizing focal lesions as well as guiding and monitoring percutaneous treatments) and outside the liver (in the kidney, vesicoureteral reflux, pancreas, traumatisms, and cerebral circulation). For each of the indications, first we describe the interpretation of the findings, then the recommended uses, and finally the limitations of the technique. Finally, we review all the other applications that have yet to be included in the EFSUMB guidelines.
    Radiología. 01/2009; 51(4).